Skip to main content

Lucence Dx Inks India Distribution Deal for Liquid Biopsy Test

NEW YORK (GenomeWeb) — Lucence Diagnostics has signed a distribution agreement for its recently launched LiquidHallMark liquid biopsy panel in India with Mumbai-based iGenetic Diagnostics, the companies announced last week.

LiquidHallMark is designed to detect clinically relevant genomic alterations — including somatic mutations, microsatellite instability, and viral DNA from ctDNA — in blood. Introduced in October, the next-generation sequencing-based test is geared toward cancers prevalent in Asia such as breast, colon, lung, and nasopharyngeal cancers.

Specific terms of the distribution deal were not disclosed.

"With iGenetic's experience and presence in India, we are confident that this partnership will drive better cancer care in India," Lucence Founder and CEO Min-Han Tan said in a statement.

Singapore-based Lucence has signed a number of distribution pacts for its cancer diagnostics in recent months, including ones with Mascots Medical and Laboratory Centre in Myanmar, Singapore Diagnostics in the Philippines, Bangkok Molecular Genetics in Thailand, and Quest Laboratories in Singapore.